A phase 3 randomized clinical trial was designed to test whether bardoxolone methyl , a nuclear factor erythroid-2-related factor 2 ( Nrf2 ) activator , slows progression to end-stage renal disease in patients with stage 4 chronic kidney disease and type 2 diabetes mellitus .